carbostyril has been researched along with Agnogenic Myeloid Metaplasia in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barosi, G; Rosti, V | 1 |
Albitar, M; Cortes, J; Garcia-Manero, G; Giles, F; Kantarjian, H; Koller, C; Kurzrock, R; O'Brien, S; Rackoff, W; Talpaz, M; Thibault, A; Thomas, D | 1 |
Gray, LA; Kaufmann, SH; Mesa, RA; Reeder, T; Schroeder, G; Tefferi, A | 1 |
Odenike, O; Tefferi, A | 1 |
Camoriano, JK; Erlichman, C; Finke, C; Geyer, SM; Kaufmann, SH; Lasho, T; Li, CY; Mesa, RA; Pardanani, A; Rivera, CE; Tefferi, A; Wright, J; Wu, W | 1 |
2 review(s) available for carbostyril and Agnogenic Myeloid Metaplasia
Article | Year |
---|---|
Novel strategies for patients with chronic myeloproliferative disorders.
Topics: Chronic Disease; Humans; Interferon alpha-2; Interferon-alpha; Janus Kinase 2; Mutation; Myeloproliferative Disorders; Nitriles; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Quinolones; Recombinant Proteins; Thalidomide | 2009 |
Conventional and new treatment options for myelofibrosis with myeloid metaplasia.
Topics: Androgens; Angiogenesis Inhibitors; Antineoplastic Agents; Azacitidine; Benzamides; Chronic Disease; Decitabine; Erythropoietin; Humans; Imatinib Mesylate; Piperazines; Primary Myelofibrosis; Pyrimidines; Quinolones; Recombinant Proteins | 2005 |
2 trial(s) available for carbostyril and Agnogenic Myeloid Metaplasia
Article | Year |
---|---|
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Blast Crisis; Drug Administration Schedule; Drug Eruptions; Endothelial Growth Factors; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Fibroblast Growth Factor 2; Hepatocyte Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Lymphokines; Male; Middle Aged; Multiple Myeloma; Nausea; Neoplasm Proteins; Primary Myelofibrosis; Quinolones; Salvage Therapy; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Bone Marrow; Female; Humans; Janus Kinase 2; Male; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Prospective Studies; Quinolones; Thrombocythemia, Essential; Treatment Outcome | 2007 |
1 other study(ies) available for carbostyril and Agnogenic Myeloid Metaplasia
Article | Year |
---|---|
In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Cell Survival; Cells, Cultured; Chromones; Colony-Forming Units Assay; Enzyme Inhibitors; Erythrocyte Count; Farnesyltranstransferase; Female; Flavonoids; GPI-Linked Proteins; Hematopoietic Stem Cells; Humans; Male; Membrane Glycoproteins; Mesothelin; Middle Aged; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Proteins; Quinolones; Thrombocythemia, Essential | 2003 |